This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ulrich, C. M. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Ulrich, C. M. Articles by Potter, J. D.

Thymidylate Synthase Promoter Polymorphism, Interaction with Folate Intake, and Risk of Colorectal Adenomas

Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 [C. M. U., J. B., J. D. P.]; Department of Epidemiology, University of Washington, Seattle, Washington 98195 [C. M. U., J. D. P.]; University of Minnesota, Minneapolis, Minnesota 55414 [L. F.]; and University of South Carolina, Columbia, South Carolina 29208 [R. B.]

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Thymidylate synthase (TS) is a key enzyme in folate metabolism and the primary target of 5-fluorouracil. A repeat polymorphism in the TS promoter enhancer region (2rpt versus 3rpt of 28 bp) is associated with decreased expression, and a 6-bp deletion in the 3'untranslated region may affect RNA stability. We investigated the role of TS polymorphisms in a case control study of adenomatous polyps (510 cases and 604 polyp-free controls). Multivariate-adjusted odds ratios (ORs; 95% confidence interval) for TSER 2rpt/3rpt and 2rpt/2rpt compared with 3rpt/3rpt were 0.8 (0.6–1.2) and 0.9 (0.6–1.3), respectively. We observed a significant gene-nutrient interaction between the TSER polymorphism and folate intake: among 3rpt/3rpt individuals (greater expression), folate intake > 440 µg/day (highest tertile) versus 440 µg/day was associated with a 2-fold decreased risk [ORs 1.0 (reference group) versus 0.5 (0.3–0.9)]. However, among 2rpt/2rpt individuals, high folate intake was associated with a 1.5-fold increased risk [ORs 0.6 (0.4–0.9) versus 0.9 (0.5–1.5; P for interaction = 0.03)]. Vitamin B₁₂ showed a similar trend (P = 0.08). No clear pattern was seen with the TS 1494del6 polymorphism. These findings raise questions regarding the molecular pathways linking folate metabolism and colorectal carcinogenesis, including whether high folate is beneficial in the presence of all metabolic genotypes.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
TS² is a key enzyme in folate metabolism and catalyzes the conversion of dUMP to dTMP. This conversion is essential for the provision of thymidine, a nucleotide needed for DNA synthesis and repair. TS is also a target for major chemotherapeutic drugs, including 5-fluorouracil. The substrate for TS, 5,10-methylene-THF, is a central metabolite in folate metabolism and is diverted into different pathways, including thymidine synthesis, purine synthesis, and toward the provision of methyl groups for DNA methylation. Colon cells are subject to rapid turnover and, thus, are the site of high rates of DNA synthesis. Furthermore, DNA repair is essential in the colonic environment, and DNA repair mechanisms can be affected by nucleotide availability (1, 2, 3) . Folate deficiency has been shown to increase several measures of DNA damage (4 , 5) , and a low folate status is consistently associated with an increased risk of colorectal cancer (6 , 7) . The human TS promoter region includes several mechanisms for gene regulation, including a cis-acting enhancer element (8) . This TSER is polymorphic, containing two or three 28-bp tandem repeats among Caucasian and Asian populations (9 , 10) . The less common double repeat is associated with 2.6-fold lower TS expression in HeLaS3 cells than the triple repeat (9) , and in vivo TS mRNA levels in tumor tissue were 3.6-fold lower among 2rpt/2rpt individuals compared with 3rpt/3rpt individuals (11) . We also reported recently on a second TS polymorphism, a 6-bp deletion at bp 1494 in the 3'UTR that may be associated with decreased mRNA levels in colorectal tumors (12 , 13) . We hypothesized that a change in TS expression may affect colon carcinogenesis and investigated the risk of colorectal adenomas associated with the two TS polymorphisms in a large case control study of colonoscopically screened men and women.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Study Subjects.
Subject recruitment for the Minnesota Cancer Prevention Research Unit case control study has been described previously (14) . Briefly, cases and controls were recruited through a multiclinic private gastroenterology practice in metropolitan Minneapolis, Digestive Healthcare. Patients (age 30–74 years) who were scheduled for colonoscopy between April 1991 and April 1994 were screened for eligibility and recruited prior to colonoscopy. Recruitment at all 10 sites was initiated at the time of scheduling with the intention of recruiting subjects with both patient and recruiter blind to the final diagnosis. The study protocol was approved by the internal review boards of the University of Minnesota, and each DH endoscopy site and written informed consent was given by each study participant.

Eligibility criteria for both cases and controls were: (a) resident of Twin cities metropolitan area; (b) age 30–74 years; (c) English speaking; (d) no known genetic syndrome associated with colonic neoplasia; and (e) no history of cancer (except nonmelanoma skin cancer), adenomatous polyps, or inflammatory bowel disease. Indications for colonoscopy have been published previously (15) , and 68% of all colonoscoped patients participated.

At the colonoscopy visit, questionnaires were collected, blood was drawn, and the colonoscopy findings were recorded. Only participants with a complete colonoscopy reaching the cecum were eligible. All polyps were removed and evaluated histologically. Patients with polyps showing invasive carcinoma were not included. Adenomatous polyp cases are those found to have 1 adenomatous polyp; controls were polyp free at colonoscopy.

Data Collection.
Data collection included information on dietary intake, physical activity, smoking habits, anthropometric measurements, medical information, demographic information, and reproductive history. When data were incomplete, study staff followed up by phone. The dietary questionnaire was an adaptation of the Willett food-frequency questionnaire, which has been studied previously for validity and repeatability. Furthermore, folate values derived from this questionnaire correlated with RBC folate levels (an indicator of long-term folate status r = 0.56).

Genotyping.
Genomic DNA from lymphocytes was extracted using the PureGene kit (Gentra Systems, Inc., Minneapolis, MN). For the analysis of the TSER 28-bp repeat polymorphism, a fragment containing the repeats was amplified using primers TS forward primer: 5'-GTGGCTCCTGCGTTTCCCCC-3' and TS reverse primer: 5'-GGCTCCGAGCCGGCCACAGGCATGGCGCGG-3' (9) . The PCR reactions contained 1 x GeneAmp buffer (Applied Biosystems, Foster City, CA), 1.5 mM MgCl₂, 200 µM deoxyribonucleotide triphosphates, 100 nM each primer, 10% DMSO, 1 unit of Amplitaq DNA polymerase (Applied Biosystems), and 100 ng of genomic DNA. Cycling conditions were one cycle of 94°C for 2 min, 35 cycles of 94°C for 30 s, 63°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 5 min. The amplified fragments were separated on a 3% NuSieve agarose gel (Biowhittacker, Rockland, ME). The fragment containing three and two repeats were 243 and 215 bp, respectively.

The 3'UTR polymorphism was analyzed by RFLP as described (12) . Briefly, a fragment containing the 6-bp deletion was amplified using primers 5'-CAAATCTGAGGGAGCTGAGT-3' and 5'-CAGATAAGTGGCAGTACAGA-3' in a reaction containing 1 x GeneAmp buffer, 2.5 mM MgCl2, 150 mM deoxyribonucleotide triphosphates, 300 nM each primer, 1 unit of AmpliTaq DNA polymerase, and 100 ng of genomic DNA. The cycling conditions were 1 cycle of 94°C for 5 min, 30 cycles of 94°C for 30 s, 58°C for 45 s, and 72°C for 45 s, and a final extension at 72°C for 5 min. The amplified fragments were digested with DraI, and the products were separated on a 3% NuSieve agarose gel. The expected fragment sizes were 70 and 88 bp for the wild-type allele and 152 bp for the variant allele.

Statistical Data Analysis.
Unconditional logistic regression models were used to obtain maximum likelihood estimates, ORs, and 95% confidence intervals. Multivariate adjustment included age, sex, body mass index (kg/m²), percentage of calories from fat, hormone replacement therapy (ever/never), and pack-years of smoking. These variables altered some risk estimates by >10%. In general, confounding effects were small and often only apparent in stratified analyses; nonetheless, a consistent multivariate adjustment was maintained throughout all analyses presented. Other factors evaluated but not found to be confounders were waist:hip ratio, regular use of aspirin or nonsteroidal anti-inflammatory drugs (at least once/week versus never), hours of physical activity, and the dietary intake variables kcal, dietary fiber, vitamin B₆, vitamin B₁₂, and alcohol. The MTHFR C677T polymorphism was also not found to confound the associations.

Effect modification of the relation between nutrient intakes and risk of adenomas by genotype was evaluated by testing for different slopes with increasing nutrient intake across genotypes. Because the allele frequency of the TSER polymorphism is known to vary by race (10) , we restricted the study population to Caucasians (who comprised 97% of the original population) for a sample size of 510 cases and 604 controls. All tests of statistical significance were two sided. SAS, version 8.2 (SAS Institute Inc., Cary, NC), was used for the analyses.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The study population and their dietary intakes have been described previously (15) , and selected characteristics are presented in Table 1 . The allele frequency of the TSER polymorphism among the controls was 0.48 with 52% heterozygotes (2rpt/3rpt) and 21% homozygous variant (2rpt/2rpt). The allele frequency of the TS 1494 6-bp deletion was 0.30 with 40% heterozygotes (6 bp/0 bp) and 10% homozygous variant (0 bp/0 bp). The two polymorphisms were in linkage disequilibrium: among those with a TSER 3rpt/3rpt genotype, 29% were found to have the TS 6 bp/6 bp genotype and 26% the 0 bp/0 bp genotype; among individuals with a TSER 2rpt/2rpt genotype, these proportions were 73 and 3%, respectively (P < 0.001). However, all genotype combinations were observed. Both variants were in Hardy-Weinberg equilibrium.

View larger version (61K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Risk of colorectal polyps associated with the TSER polymorphism, stratified by folate (A) or vitamin B-12 (B) intake.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
To our knowledge, this is the first study investigating the relevance of TS polymorphisms in colorectal carcinogenesis. As with other polymorphisms in folate metabolism (15 , 17) , upon stratification by a relevant exposure (folate), an informative pattern emerged. We observed a statistically significant gene environment interaction, with a decreased adenoma risk associated with high folate intakes among individuals with the TSER wild-type (3rpt/3rpt) genotype and the opposite association (increased risk with high folate intake) among individuals with lower TS expression (2rpt/2rpt). Similar trends were observed for vitamin B-12 intake, which is an essential cofactor for another key enzyme in folate metabolism, methionine synthase.

Under low or medium folate intakes and in the presence of a MTHFR TT genotype, which can be considered to further impair folate status, the TSER variant genotypes were associated with a decreased risk of colorectal adenoma. Thus, we hypothesize that the lower TS expression (2rpt/2rpt or 3rpt/2rpt genotypes) may have a "folate-sparing" effect that reduces risk of adenoma.

The finding of a decreased risk associated with lower TS expression in the presence of low-folate intake (Fig. 1) was unexpected. Previously, several groups have hypothesized that the inverse association between the C677T MTHFR polymorphism and colorectal carcinogenesis may be attributable to a greater diversion of the relevant substrate (5,10-methylene-THF toward nucleotide synthesis; TS and several enzymes involved in purine synthesis; Refs. 15 , 17 , and 18 ). TS converts dUMP to dTMP, and it has been shown that folate deficiency can lead to uracil misincorporation associated with an increased risk of double-strand breaks (4 , 5) . Our findings, however, suggest that the purine synthesis pathway may be a relevant mechanism linking folate metabolism to colorectal carcinogenesis.

Two potential explanations could reconcile our findings with the existing knowledge about this pathway: (a) it is likely that, within the folate pathway, a balance exists between the provision of 5,10-methylene-THF for thymidine synthesis, purine synthesis, and the provision of methyl groups for methylation reactions. On the basis of biochemical models in pig liver, the cellular concentration of 5,10-methylene-THF regulates the flux of this metabolite into the pathways leading to nucleotide synthesis and methionine regeneration (19) . It is unclear whether variations in enzyme function could affect these regulatory mechanisms; and (b) it may be that an adequate provision of 5,10-methylene-THF for purine synthesis is key. Depurination is the most common form of spontaneous DNA damage, with an estimated 10,000 depurinations/cell/day (20 , 21) . Although an abundance of apurinic endonucleases efficiently repairs this damage, quantitative measurements show that abasic sites are present in cellular DNA, with a steady-state level of 5–10,000 lesions/cell/day (21) . Thus, depurination may be the major challenge the body faces on a continuous basis, and the provision of an adequate supply of purines may be an important prerequisite for repair. Accordingly, in the presence of low folate, it may be that purine synthesis is the most protected pathway.

Perturbations of nucleotide pools attributable to folate deficiency have been associated with inhibited DNA repair and increased mutation rates (1 , 2) . However, the role of purine depletion in mutagenesis is unclear. There is no evidence that folate deficiency results in a greater prevalence of apurinic sites, but, to our knowledge, this has not yet been investigated. An effect of folate deficiency on purine pools has been documented in one study (22) . The most promising evidence in support of a link between folate deficiency, purine synthesis, and DNA damage stems from investigations in an in vitro model of folate-deficient erythropiesis, indicating that decreased de novo synthesis of purines plays an equally important role as decreased de novo synthesis of thymidylate in the pathogenesis of megaloblastic anemia (23) .

Our study had several limitations. The study population was comprised of individuals undergoing screening by colonoscopy and was thus not necessarily representative of the general population. The major advantage of this clinic-based approach, nonetheless, is the unambiguous distinction between patients with adenomas and polyp-free controls. The indications for colonoscopy were not related to the TS genotype or to intakes of the nutrients investigated. Thus, a bias attributable to differences in indication for colonoscopy is unlikely. A strength of the study is the relatively large study size, permitting us to investigate gene-nutrient interactions. However, for analyses investigating genotype combinations (MTHFR and TS) in conjunction with nutritional status, our statistical power was limited.

In summary, previous research on MTHFR polymorphisms has illustrated the importance of genetic variability in the folate pathway in colorectal carcinogenesis. We here extend these findings to a common polymorphism in TS, which modifies risk depending on folate status (and possibly vitamin B-12 status). Our findings raise questions regarding the molecular pathways linking folate metabolism to colorectal carcinogenesis, especially including whether folate is beneficial in the presence of all metabolic genotypes. It may also have implications for the pharmacogenetics of antifolate drugs, such as 5-fluorouracil.

	ACKNOWLEDGMENTS

 
We thank Angela Bush for technical assistance with the DNA genotyping, Rachel Sparks for general research assistance, and Mari Nakayoshi for assistance with graphics and word processing.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Fred Hutchinson Cancer Research Center, Cancer Prevention Research Program, 1100 Fairview Avenue N, MP-900, Seattle, WA 98109-1024. Phone: (206) 667-7617; Fax: (206) 667-7850; E-mail: nulrich{at}fhcrc.org

² The abbreviations used are: TS, thymidylate synthase; THF, tetrahydrofolate; MTHFR, 5,10-methylenetetrahydrofolate reductase; TSER, thymidylate synthase enhancer region; OR, odds ratio; UTR, untranslated region.

Received 3/18/02. Accepted 4/23/02.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. James S. J., Basnakian A. G., Miller B. J. In vitro folate deficiency induces deoxynucleotide pool imbalance, apoptosis, and mutagenesis in Chinese hamster ovary cells. Cancer Res., 54: 5075-5080, 1994.[Abstract/Free Full Text]
2. Snyder R. D. Effects of nucleotide pool imbalances on the excision repair of ultraviolet-induced damage in the DNA of human diploid fibroblasts. Basic Life Sci., 31: 163-173, 1985.[Medline]
3. Mattano S. S., Palella T. D., Mitchell B. S. Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. Cancer Res., 50: 4566-4571, 1990.[Abstract/Free Full Text]
4. Duthie S. J. Folic acid deficiency and cancer: mechanisms of DNA instability. Br. Med. Bull., 55: 578-592, 1999.[Abstract/Free Full Text]
5. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat. Res., 475: 57-67, 2001.[Medline]
6. Potter J. D. Colorectal cancer: molecules and populations. J. Natl. Cancer Inst., 91: 916-932, 1999.[Abstract/Free Full Text]
7. Choi S. W., Mason J. B. Folate and carcinogenesis: an integrated scheme. J. Nutr., 130: 129-132, 2000.[Abstract/Free Full Text]
8. Kaneda S., Takeishi K., Ayusawa D., Shimizu K., Seno T., Altman S. Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res., 15: 1259-1270, 1987.[Abstract/Free Full Text]
9. Horie N., Aiba H., Oguro K., Hojo H., Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct., 20: 191-197, 1995.[Medline]
10. Marsh S., Collie-Duguid E. S., Li T., Liu X., McLeod H. L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics, 58: 310-312, 1999.[Medline]
11. Pullarkat S. T., Stoehlmacher J., Ghaderi V., Xiong Y-P., Ingles S. A., Sherrod A., Warren R., Tsao-Wei D., Groshen S., Lenz H-J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics, 1: 65-70, 2001.
12. Ulrich C., Bigler J., Velicer C., Greene E., Farin F., Potter J. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomark. Prev., 9: 1381-1385, 2000.[Abstract/Free Full Text]
13. Lenz H-J., Zhang W., Zhahedy S., Gil J., Yu M., Stoehlmacher J. A 6 base-pair deletion in the 3'UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors. A possible candidate gene for colorectal cancer risk. Proc. AACR, 43: 660 2002.
14. Potter J. D., Bostick R. M., Grandits G. A., Fosdick L., Elmer P., Wood J., Grambsch P., Louis T. A. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol. Biomark. Prev., 5: 779-784, 1996.[Abstract]
15. Ulrich C. M., Kampman E., Bigler J., Schwartz S. M., Chen C., Bostick R., Fosdick L., Beresford S. A., Yasui Y., Potter J. D. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction?. Cancer Epidemiol. Biomark. Prev., 8: 659-668, 1999.[Abstract/Free Full Text]
16. Levine A. J., Siegmund K. D., Ervin C. M., Diep A., Lee E. R., Frankl H. D., Haile R. W. The methylenetetrahydrofolate reductase 677C–>T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol. Biomark. Prev., 9: 657-663, 2000.[Abstract/Free Full Text]
17. Ma J., Stampfer M. J., Giovannucci E., Artigas C., Hunter D. J., Fuchs C., Willett W. C., Selhub J., Hennekens C. H., Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res., 57: 1098-1102, 1997.[Abstract/Free Full Text]
18. Chen J., Giovannucci E. L., Hunter D. J. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U. S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. J. Nutr., 129: 560S-564S, 1999.
19. Green J. M., MacKenzie R. E., Matthews R. G. Substrate flux through methylenetetrahydrofolate dehydrogenase: predicted effects of the concentration of methylenetetrahydrofolate on its partitioning into pathways leading to nucleotide biosynthesis or methionine regeneration. Biochemistry, 27: 8014-8022, 1988.[Medline]
20. Lindahl T., Nyberg B. Rate of depurination of native deoxyribonucleic acid. Biochemistry, 11: 3610-3618, 1972.[Medline]
21. Nakamura J., Swenberg J. A. Endogenous apurinic/apyrimidinic sites in genomic DNA of mammalian tissues. Cancer Res., 59: 2522-2526, 1999.[Abstract/Free Full Text]
22. Walzem R. L., Clifford C. K., Clifford A. J. Purine synthesis and reutilization in folate-deficient rat hepatocytes. J. Nutr., 113: 1032-1038, 1983.
23. Koury M. J., Price J. O., Hicks G. G. Apoptosis in megaloblastic anemia occurs during DNA synthesis by a p53-independent, nucleoside-reversible mechanism. Blood, 96: 3249-3255, 2000.[Abstract/Free Full Text]

This article has been cited by other articles:

				M.P. GALLEGOS-ARREOLA, J.E. GARCIA-ORTIZ, L.E. FIGUERA, A.M. PUEBLA-PEREZ, G. MORGAN-VILLELA, and G.M. ZUNIGA-GONZALEZ Association of the 677C ->T Polymorphism in the MTHFR Gene with Colorectal Cancer in Mexican Patients Cancer Genomics Proteomics, May 1, 2009; 6(3): 183 - 188. [Abstract] [Full Text] [PDF]

				J. M. Genkinger, D. Spiegelman, K. E. Anderson, L. Bergkvist, L. Bernstein, P. A. van den Brandt, D. R. English, J. L. Freudenheim, C. S. Fuchs, G. G. Giles, et al. Alcohol Intake and Pancreatic Cancer Risk: A Pooled Analysis of Fourteen Cohort Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 765 - 776. [Abstract] [Full Text] [PDF]

				E. Goekkurt, S.-E. Al-Batran, U. Mogck, C. Pauligk, J. T. Hartmann, M. Kramer, E. Jaeger, G. Ehninger, and J. Stoehlmacher Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Ann. Onc., March 1, 2009; 20(3): 481 - 485. [Abstract] [Full Text] [PDF]

				T. J. Lightfoot, J. H. Barrett, T. Bishop, E. L. Northwood, G. Smith, M. J.V. Wilkie, R. J.C. Steele, F. A. Carey, T. J. Key, R. Wolf, et al. Methylene Tetrahydrofolate Reductase Genotype Modifies the Chemopreventive Effect of Folate in Colorectal Adenoma, but not Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2421 - 2430. [Abstract] [Full Text] [PDF]

				J. C. Figueiredo, A. J. Levine, M. V. Grau, O. Midttun, P. M. Ueland, D. J. Ahnen, E. L. Barry, S. Tsang, D. Munroe, I. Ali, et al. Vitamins B2, B6, and B12 and Risk of New Colorectal Adenomas in a Randomized Trial of Aspirin Use and Folic Acid Supplementation Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2136 - 2145. [Abstract] [Full Text] [PDF]

				C. M. Ulrich, M. Neuhouser, A. Y. Liu, A. Boynton, J. F. Gregory III, B. Shane, S. J. James, M. C. Reed, and H. F. Nijhout Mathematical Modeling of Folate Metabolism: Predicted Effects of Genetic Polymorphisms on Mechanisms and Biomarkers Relevant to Carcinogenesis Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1822 - 1831. [Abstract] [Full Text] [PDF]

				A D. Smith, Y.-I. Kim, and H. Refsum Is folic acid good for everyone? Am. J. Clinical Nutrition, March 1, 2008; 87(3): 517 - 533. [Abstract] [Full Text] [PDF]

				A. Y. Jung, E. M. Poole, J. Bigler, J. Whitton, J. D. Potter, and C. M. Ulrich DNA Methyltransferase and Alcohol Dehydrogenase: Gene-Nutrient Interactions in Relation to Risk of Colorectal Polyps Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 330 - 338. [Abstract] [Full Text] [PDF]

				R. A. Hubner, K. R. Muir, J.-F. Liu, G. S. Sellick, R. F.A. Logan, M. Grainge, N. Armitage, I. Chau, R. S. Houlston, and The United Kingdom Colorectal Adenoma Prevention C Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1607 - 1613. [Abstract] [Full Text] [PDF]

				S. Niclot, Q. Pruvot, C. Besson, D. Savoy, E. Macintyre, G. Salles, N. Brousse, B. Varet, P. Landais, P. Taupin, et al. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas Blood, July 1, 2006; 108(1): 278 - 285. [Abstract] [Full Text] [PDF]

				C. M. Ulrich, H. F. Nijhout, and M. C. Reed Mathematical modeling: epidemiology meets systems biology. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 827 - 829. [Full Text] [PDF]

				E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al. Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment J. Clin. Oncol., April 1, 2006; 24(10): 1603 - 1611. [Abstract] [Full Text] [PDF]

				C. M. Ulrich and J. D. Potter Folate supplementation: too much of a good thing? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 189 - 193. [Full Text] [PDF]

				T. J. Lightfoot, C. F. Skibola, E. V. Willett, D. R. Skibola, J. M. Allan, F. Coppede, P. J. Adamson, G. J. Morgan, E. Roman, and M. T. Smith Risk of Non-Hodgkin Lymphoma Associated with Polymorphisms in Folate-Metabolizing Genes Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2999 - 3003. [Abstract] [Full Text] [PDF]

				C. M. Ulrich, K. Curtin, J. D. Potter, J. Bigler, B. Caan, and M. L. Slattery Polymorphisms in the Reduced Folate Carrier, Thymidylate Synthase, or Methionine Synthase and Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2509 - 2516. [Abstract] [Full Text] [PDF]

				C. M. Ulrich Nutrigenetics in Cancer Research--Folate Metabolism and Colorectal Cancer J. Nutr., November 1, 2005; 135(11): 2698 - 2702. [Abstract] [Full Text] [PDF]

				Z. Zhang, Y. Xu, J. Zhou, X. Wang, L. Wang, X. Hu, J. Guo, Q. Wei, and H. Shen Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions associated with risk of gastric cancer in South China: a case-control analysis Carcinogenesis, October 1, 2005; 26(10): 1764 - 1769. [Abstract] [Full Text] [PDF]

				W. Tan, X. Miao, L. Wang, C. Yu, P. Xiong, G. Liang, T. Sun, Y. Zhou, X. Zhang, H. Li, et al. Significant increase in risk of gastroesophageal cancer is associated with interaction between promoter polymorphisms in thymidylate synthase and serum folate status Carcinogenesis, August 1, 2005; 26(8): 1430 - 1435. [Abstract] [Full Text] [PDF]

				E. K. Wei, E. Giovannucci, J. Selhub, C. S. Fuchs, S. E. Hankinson, and J. Ma Plasma Vitamin B6 and the Risk of Colorectal Cancer and Adenoma in Women J Natl Cancer Inst, May 4, 2005; 97(9): 684 - 692. [Abstract] [Full Text] [PDF]

				Q. Shi, Z. Zhang, A. S. Neumann, G. Li, M. R. Spitz, and Q. Wei Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer Carcinogenesis, March 1, 2005; 26(3): 649 - 656. [Abstract] [Full Text] [PDF]

				J. Chen, C. Kyte, W. Chan, J. G. Wetmur, C. S. Fuchs, and E. Giovannucci Polymorphism in the Thymidylate Synthase Promoter Enhancer Region and Risk of Colorectal Adenomas Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2247 - 2250. [Abstract] [Full Text] [PDF]

				J. Zhang, Y. Cui, G. Kuang, Y. Li, N. Wang, R. Wang, W. Guo, D. Wen, L. Wei, F. Yu, et al. Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma Carcinogenesis, December 1, 2004; 25(12): 2479 - 2485. [Abstract] [Full Text] [PDF]

				Z. Zhang, Q. Shi, E. M. Sturgis, M. R. Spitz, W. K. Hong, and Q. Wei Thymidylate Synthase 5'- and 3'-Untranslated Region Polymorphisms Associated with Risk and Progression of Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., December 1, 2004; 10(23): 7903 - 7910. [Abstract] [Full Text] [PDF]

				Z. Kemp, C. Thirlwell, O. Sieber, A. Silver, and I. Tomlinson An update on the genetics of colorectal cancer Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R177 - R185. [Abstract] [Full Text] [PDF]

				C. F. Skibola, M. S. Forrest, F. Coppede, L. Agana, A. Hubbard, M. T. Smith, P. M. Bracci, and E. A. Holly Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma Blood, October 1, 2004; 104(7): 2155 - 2162. [Abstract] [Full Text] [PDF]

				O. Bashir, A.J. FitzGerald, and R.A. Goodlad Both suboptimal and elevated vitamin intake increase intestinal neoplasia and alter crypt fission in the ApcMin/+ mouse Carcinogenesis, August 1, 2004; 25(8): 1507 - 1515. [Abstract] [Full Text] [PDF]

				L. Sharp and J. Little Polymorphisms in Genes Involved in Folate Metabolism and Colorectal Neoplasia: A HuGE Review Am. J. Epidemiol., March 1, 2004; 159(5): 423 - 443. [Abstract] [Full Text] [PDF]

				K. Curtin, J. Bigler, M. L. Slattery, B. Caan, J. D. Potter, and C. M. Ulrich MTHFR C677T and A1298C Polymorphisms: Diet, Estrogen, and Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 285 - 292. [Abstract] [Full Text] [PDF]

				K. Uchida, K. Hayashi, K. Kawakami, S. Schneider, J. M. Yochim, H. Kuramochi, K. Takasaki, K. D. Danenberg, and P. V. Danenberg Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in the TS Gene Clin. Cancer Res., January 15, 2004; 10(2): 433 - 439. [Abstract] [Full Text] [PDF]

				E. L. Goode, J. D. Potter, J. Bigler, and C. M. Ulrich Methionine Synthase D919G Polymorphism, Folate Metabolism, and Colorectal Adenoma Risk Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 157 - 162. [Abstract] [Full Text] [PDF]

				K. Kawakami, A. Ruszkiewicz, G. Bennett, J. Moore, G. Watanabe, and B. Iacopetta The Folate Pool in Colorectal Cancers Is Associated with DNA Hypermethylation and with a Polymorphism in Methylenetetrahydrofolate Reductase Clin. Cancer Res., December 1, 2003; 9(16): 5860 - 5865. [Abstract] [Full Text] [PDF]

				J. Chen, D. J. Hunter, M. J. Stampfer, C. Kyte, W. Chan, J. G. Wetmur, R. Mosig, J. Selhub, and J. Ma Polymorphism in the Thymidylate Synthase Promoter Enhancer Region Modifies the Risk and Survival of Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 958 - 962. [Abstract] [Full Text] [PDF]

				A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman Frontiers in Cancer Prevention Research Cancer Res., September 15, 2003; 63(18): 5649 - 5655. [Full Text] [PDF]

				M. V. Mandola, J. Stoehlmacher, S. Muller-Weeks, G. Cesarone, M. C. Yu, H.-J. Lenz, and R. D. Ladner A Novel Single Nucleotide Polymorphism within the 5' Tandem Repeat Polymorphism of the Thymidylate Synthase Gene Abolishes USF-1 Binding and Alters Transcriptional Activity Cancer Res., June 1, 2003; 63(11): 2898 - 2904. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ulrich, C. M. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Ulrich, C. M. Articles by Potter, J. D.